David A. Siegel Biocryst Pharmaceuticals Inc Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 3,220,712 shares of BCRX stock, worth $34 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
3,220,712
Previous 2,499,812
28.84%
Holding current value
$34 Million
Previous $18.8 Million
28.5%
% of portfolio
0.06%
Previous 0.05%
Shares
31 transactions
Others Institutions Holding BCRX
# of Institutions
293Shares Held
177MCall Options Held
721KPut Options Held
489K-
Vanguard Group Inc Valley Forge, PA21.7MShares$229 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$211 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.93MShares$94.3 Million5.64% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.7MShares$91.9 Million1.06% of portfolio
-
State Street Corp Boston, MA7.81MShares$82.5 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.96B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...